



**Europass**  
**Curriculum Vitae**

**Personal  
Information**

Name **PATRIZIA**  
Surname **Russo**  
Address

E-Mail **patrizia.russo@uniroma5.it**

Nationality **Italiana**

Place and Date of  
Birth

Gender

## Work Experiences

### Period

- July 2021 - Present – Associate Professor (MED04: General Pathology) at San Raffaele University, Rome, Italy
- June 2019 - June 2021 - Researcher (RTD) at San Raffaele University, Rome, Italy.
- December 2009 - Present - Affiliated Senior Researcher, Unit of Clinical and Molecular Epidemiology, IRCCS "San Raffaele Pisana" Rome, Italy.
- January 2006 - November 2009 - Head of Operational Unit (UOS), Unit for Lung Cancer, Department of Advanced Diagnostic Technology, National Cancer Institute, Genoa, Italy.
- December 1996 - December 2005 - Head of Molecular Pathology Section (commissioner's order No. 2060 of 3/12/96), Department of Chemical Carcinogenesis / Experimental Oncology, National Cancer Institute, Genoa, Italy.
- December 1992 - May 1994 - Senior Assistant Researcher (art. No. 7 DPR No. 438), Department of Chemical Carcinogenesis, National Cancer Institute, Genoa, Italy.
- May 1987 - April 1994 - Assistant Researcher, Department of Chemical Carcinogenesis, National Cancer Institute, Genoa, Italy.
- September 1986 - April 1987 - Assistant (renewable appointment), Department of Mutagenesis, National Cancer Institute, Genoa, Italy.
- April 1980 - December 1983 - Assistant Researcher (renewable appointment), Department of Chemical Carcinogenesis, National Cancer Institute, Genoa, Italy.
- August 1979 - March 1980 - Volunteer Researcher, Department of Oncology, University of Genoa, Italy.
- December 1978 - July 1979 - Volunteer Researcher, Department of Microbiology, University of Genoa, Italy.
- December 1978-July 1979.-Guest Investigator, Dpt. of Microbiology, University of Genoa, Italy.
- June 1976-November 1978.-Internship Student, Dpt. of Microbiology, University of Genoa, Italy.

## **International experiences**

### **Period**

- May-July 1987 - Guest Investigator, Laboratory of Molecular Pharmacology, DNA Topology Section, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, USA
- July 1997 - January 1998 - Guest Investigator, Laboratory of Molecular Pharmacology, Cell Cycle Checkpoint Section, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, USA.

## **National Scientific Qualification**

- January 2014 – Associate Professor 06/A2 GENERAL PATHOLOGY AND CLINICAL PATHOLOGY (MED/04). Related to:  
MED/02, HISTORY OF MEDICINE  
MED/05, CLINICAL PATHOLOGY  
MED/06, ONCOLOGY  
MED/46, TECHNICAL SCIENCES OF MEDICINE AND LABORATORY
- January 2014 – Associate professor 05/E2 - MOLECULAR BIOLOGY (BIO/11). Related to:  
BIO/10, BIOCHEMISTRY  
BIO/12, CLINICAL BIOCHEMISTRY AND CLINICAL MOLECULAR BIOLOGY  
MED/49, APPLIED TECHNICAL SCIENCES IN DIETETICS
- December 2021 – Full Professor 06/N1 - HEALTH PROFESSIONS AND APPLIED MEDICAL TECHNOLOGIES (MED50)

**Teaching activities****Period**

- June 2019 - Present: General Pathology (MED04), Faculty of Human Nutrition Sciences, San Raffaele University, Rome, Italy.
- October 2022 - Present: History of Medicine, Faculty of Human Nutrition Sciences, San Raffaele University, Rome, Italy.
- March 2018 - October 2018: Internship Tutor in collaboration with Sapienza University of Rome, Master's Degree in Biotechnology. Candidate: Alessia Santoro.
- November 2010 - October 2012: Aggregate Professor of Applied Biology, Faculty of Nursing Sciences, "Tor Vergata" University (Rome 2), Rome, Italy.
- November 2001 - November 2005: Aggregate Professor of Translational Research in Thoracic Oncology, School of Specialization in Thoracic Surgery, University of Genoa, Italy.
- November 2000 - November 2001: Aggregate Professor of Developmental Biology, Faculty of Biological Sciences, University of Genoa, Italy.
- November 1995 - November 2000: Aggregate Professor of Experimental Oncology, School of Specialization in Experimental and Clinical Oncology, University of Genoa, Italy.

**Occupation or position held**

Associate Professor

**Main activities and responsibilities**

Research on nicotinic receptors, COPD, Smoking, Personalized Medicine, SARS-CoV-2, Virome

**"Name and address of the employer**

San Raffaele University [Multiversity Group], Via di Valcannuta 247-249, Roma Italia.

**Type of business or sector**

Research in Biology and Medicine; Training in Biology and Human Nutrition Science, Systems Medicine

## Education and training

### Period

- 2022: Master's Degree in "Innovating Digital Teaching in Universities: Objectives, Strategies, and Tools" at Politecnico di Milano.
- 1982: Specialization in Microbiology with a technical focus. Thesis title: Quantitative correlation between carcinogenicity, mutagenicity in *Salmonella Typhimurium*, and DNA damage in vivo of 16 aromatic amines and azo compounds." Advisor: Prof. Giancarlo Schito. Grade obtained: 50/50. University of Genoa, Italy.
- 1978-1982: Four-year Specialization School in Microbiology, Faculty of Medicine and Surgery (recognized title in the European Union), University of Genoa, Italy.
- 1978: Bachelor's Degree in Biological Sciences. Thesis title: "Isolation of an HFR strain of *Klebsiella Pneumoniae* using the suppressive integration technique." Advisor: Prof. Giuseppe Satta. Grade obtained: 110/110 Summa cum Laude. University of Genoa, Italy.
- June 1976 - November 1978: Internship Student, Department of Microbiology, University of Genoa, Italy.
- 1974-1978: Faculty of Biological Sciences (Old System), University of Genoa, Italy.
- 1974: Classical High School Diploma. Liceo-Ginnasio Giuseppe Mazzini, Genoa, Italy. Grade obtained: 60/60.
- 1984: Pilgrims Advanced English, University of Kent, Canterbury, UK.

**Personal skills  
and  
competences**

In the early stages of her career, she conducted studies on chemical carcinogenesis, examining the effects of various chemicals (aromatic amines, polycyclic aromatic hydrocarbons, drugs) in inducing DNA damage evaluated with different methods: alkaline elution technique, viscometry and fluorimetric methods, and comet assay. Some of these studies were funded by the Strategic Mutagenesis Grant Project "Genotoxicity of chemical and physical agents" granted by CNR (Rome, Italy). In 1985, she was involved in two international collaborative studies sponsored by the International Programme on Chemical Safety (IPCS) to assess short-term genotoxicity tests.

Since 1987, she has worked in the field of molecular pharmacology. In 1987, after receiving an international Yamagiwa-Yoshida scholarship from UICC (Geneve, Switzerland), she attended the Molecular Pharmacology Laboratory at NCI-NIH (Bethesda-USA). After acquiring specific skills in molecular pharmacology, she studied the molecular action mechanism of caffeine, and then the combination of antitumor drugs with cytokines with the aim of improving the therapeutic index. Part of the studies were funded by AIRC (Milan-Italy), CNR (Rome-Italy), and NATO (Brussels-Belgium).

From 1995, she studied the sensitivity/resistance relationship and p53 concerning new experimental antineoplastic drugs such as farnesyltransferase inhibitors. She received a scholarship from FIRC (Milan-Italy) to join the Molecular Pharmacology Laboratory of NCI-NHI (Bethesda-USA). These studies were supported by the EU (Ispra-Italy).

From 2000, she began studying the biology of lung cancer and mesothelioma. In 2001, she was involved in the "Scientific and Technological Cooperation Italy-Russia" as the supervisor of a team studying the role of the non-neuronal cholinergic system in cell growth. She has been involved in both early diagnosis of lung cancer in smokers and the development of new drugs, producing significant results. These studies were supported by the Ministry of Health, the Compagnia di San Paolo Foundation (Turin-Italy), the CARIGE Foundation (Genoa Italy). She studied the effects of organophosphate compounds on the cholinergic stem cell system. These studies were supported by the local government of the Liguria Region (Genoa-Italy).

Since 2008, she initiated collaboration with the Hebrew University (Jerusalem-Israel) to study the different roles played by the cholinergic system in neuronal and non-neuronal cells, with particular attention to nicotine dependence, lung diseases, and Alzheimer's disease.

From 2009, she started working in Systems Medicine, focusing on lung diseases and pulmonary rehabilitation of COPD) with the ultimate goal of developing and validating a system for a comprehensive assessment of the profile of COPD patients based on the analysis of different domains.

Since March 2020, she has been studying the role of nicotine in SARS-CoV-2 infection in collaboration with the University of Insubria [Varese] and the Lazzaro Spallanzani Institute [Rome].

She is UO (Operational Unit) responsible of the grant: TTV-virome prediction of dysregulated immunity and clinical differential diagnosis n. B53D2300376006/G53D23000700001 AWARDED by MUR (Ministry of University and Research) in Rome, Italy, from 2023 to 2025.

Her h-index is 38 according to Scopus, and she has 181 published works. Her Scopus Author ID is 57192333601, her ORCID ID is 0000-0003-1745-7827, and her RESEARCH ID is J-8767-2016.

Mother tongue	<b>Italian</b>
Other languages	<b>English, French, Modern Hebrew, Biblical Hebrew</b>

## Honors and Awards

- November 2023 The paper: Nicotine: From Discovery to Biological Effects by Sansone L, Milani F, Fabrizi R, Belli M, Cristina M, Zagà V, de Iure A, Cicconi L, Bonassi S, **Russo P.** Int J Mol Sci. 2023 Sep 26;24(19):14570 was considered the best paper by the Scientific committee of the MDPI group
- Today-2002 - Expert European Community (EX2002B000676 personal code) Brussels, Belgium.
- 2011 - 'Addictive Disorders' Scholarship from the Neuroscience School of Advanced Studies (Siena, Italy).
- 1997 - Scholarship for foreign studies, Italian Foundation for Cancer Research (FIRC, Milan, Italy) "Liliana Momigliano Sacerdote-Martha Galle."
- 1987 - Yamagiwa-Yoshida Memorial International Cancer Study Grant by the International Union Against Cancer (UICC, Geneva, Switzerland).

## Organization of international groups

- Evaluation of short-term tests for carcinogens: Report of the IPCS's collaborative study on in vivo assays, Cambridge, United Kingdom, Cambridge University Press, Vol. 1 & 2; Report of the international collaborative study, Amsterdam, Oxford, New York, Elsevier Science Publishers (Progress in Mutation Research, Vol. 1)].
- Evaluator for the Jordan Research Council.
- Evaluator for the Kuwait Foundation for the Advancement of Sciences (KFAS), State of Kuwait.
- Evaluator for the Research Council, Sultanate of Oman.
- Evaluator for the Austrian Science Fund.
- Evaluator for the ANR (Agence Nationale de la Recherche), France.
- Studies on a promising anticancer molecule of marine origin: results of an interdisciplinary study [Recent Advances in Biology, Biophysics, Bioengineering And Computational Chemistry, ISSN: 1790-5125].
- Reviewer for Nature Communications.
- Scientific Bases for the Definition of Clinical Guidelines for Lung Tumors: Consensus Group, CNR-MIUR Oncology Strategic Projects, Rome, Italy.
- Multicentric Prospective Study COSMO-IT (Covid-19 and smoking in Italy) [doi: 10.23750/abm.v91i3.10373].
- ClinicalTrials.gov Identifier: NCT04394299 Cognitive Impairment in COPD Patients (RESCOG).
- Member of the Technical Scientific Committee, Italian Society of Tobacco Addiction (SITAB)




**Patents** 2005 - Co-holder of Italian patent No. M112005A000534.  
"Antineoplastic activity of a polymeric molecule isolated from a Mediterranean marine sponge," Rome, Italy.

**Level in the national or international classification** H-index = 38 (Scopus).  
Scopus Author ID: 57192333601.  
ORCID ID: 0000-0003-1745-7827.  
RESEARCH ID: J-8767-2016.

**IL SOTTOSCRITTO, A CONOSCENZA DI QUANTO PRESCRITTO DALL'ART. 76 DEL D.P.R. 28 DICEMBRE 2000 N. 445, SULLA RESPONSABILITÀ PENALE CUI PUÒ ANDARE INCONTRO IN CASO DI FALSITÀ IN ATTI E DI DICHIARAZIONI MENDACI, NONCHÉ DI QUANTO PRESCRITTO DALL'ART. 75 DEL D.P.R. 28 DICEMBRE 2000 N. 445, SULLA DECADENZA DAI BENEFICI EVENTUALMENTE CONSEGUENTI AL PROVVEDIMENTO EMANATO SULLA BASE DI DICHIARAZIONI NON VERITIERE, AI SENSI E PER GLI EFFETTI DEL CITATO D.P.R. N. 445/2000 E SOTTO LA PROPRIA PERSONALE RESPONSABILITÀ DICHIARA CHE TUTTE LE INFORMAZIONI CONTENUTE NEL PROPRIO CURRICULUM VITAE SONO VERITIERE**

**I, aware of what is prescribed by Article 76 of Presidential Decree of December 28, 2000, No. 445, regarding the criminal liability that may be incurred in case of falsehood in documents and false statements, as well as what is prescribed by Article 75 of Presidential Decree of December 28, 2000, No. 445, regarding the forfeiture of benefits that may arise from the measure issued based on untrue statements, in accordance with the aforementioned Presidential Decree No. 445/2000 and under my personal responsibility, declare that all the information contained in my curriculum vitae is true**

**Roma, June 2024**



## Appendix A. Editorial Activities

**Editorial Board:** Recent Patents on anti-cancer drug discovery <https://benthamscience.com/journals/recent-patents-on-anti-cancer-drug-discovery/editorial-board/#top>

**Editorial Board** Current Medicine Chemistry <https://benthamscience.com/journals/current-medicinal-chemistry/editorial-board/#top>

**Editorial Board** Current Medicine Chemistry <https://benthamscience.com/journals/current-medicinal-chemistry/editorial-board/#top>

**Editorial Board** Molecules <https://www.mdpi.com/journal/molecules/editors>

**Editorial Board** International Journal of Molecular Sciences <https://www.mdpi.com/journal/ijms/editors>

**Guest Editors:** Patrizia Russo, Alfredo Cesario and Alessio Cardinale Special Issue alpha7-nicotinic receptors ( $\alpha$ -nAChR): one target different diseases. Current Drug Targets, Volume 13, 2012, Issue number 5 DOI: 10.2174/138945012800398991

**Guest Editor** Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy Journal Name: Current Pharmaceutical Design Volume 20 , Issue 38 , 2014 DOI : 10.2174/1381612820666140316132652

**Guest Editor** Special Issue "Marine Compounds in Neurodegenerative Diseases" Marine Drugs

**Guest Editor** Special Issue "Chronic Obstructive Pulmonary Disease" for the International Journal of Molecular Sciences (IJMS, IF 4.556, <http://www.mdpi.com/journal/ijms>)

## **Appendix B: Proceedings and Meetings (including Invited Speaker) 2006-Today**

### **1. 97th AACR Annual Meeting: 2006 April 1-5, 2006 • Washington, DC**

Section: Experimental and Molecular Therapeutics 35: Identification and Characterization of Novel Cellular Targets

Abstract Title: Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system

Authors: Patrizia A. Russo, Fausto Sessa, Alessia Catassi, Silvia Viaggi, Michele Cilli, Emanuela Ognio, Guido Doria-Miglietta, Massimo Paolucci, Andrea Calcaterra, Andrea Pericelli, Massimo Fini, Alfredo Cesario, Pierluigi Granone, Denis Servent and Lorenzo Dominioni

Published on: Cancer Res October 22 2014 66 (8 Supplement) 1085-1085.

### **2. RT14 (2006) : Toxins and Cancer French Society on Toxinology Paris Francia**

#### **Invited Speaker**

Title presentation: Alpha-cobratoxin, a natural  $\alpha 7$ -nicotinic receptor antagonist, as putative anticancer drug in Non Small Cell Lung Cancer

Author: Patrizia RUSSO

### **3. AACR Annual Meeting--Apr 12-16, 2008; San Diego, CA**

Section: Cellular and Molecular Biology

Abstract Title: Acetylcholine pathways: Involvement in non small cell lung cancer growth and death.

Authors: Laura Paleari, Alessia Catassi, Zita Cavalieri, Cristina Bruzzo, Alessia Grozio, Denis Servent, Gilles Mourier, Carole Fruchart-Gaillard, Alfredo Cesario and Patrizia Russo

Published on: Cancer Res October 8 2014 68 (9 Supplement) 3537-3537.

### **4. AACR Centennial Conference November 3-6, 2008 • Jerusalem, Israel**

Section: Translational Cancer Medicine 2008: Bridging the Lab and Clinic in Cancer Medicine

### **5. RT16 (2008) : Toxins and neuronal and non-neuronal cholinergic functions The SFET - French Society on Toxinology, Parigi Francia**

#### **Invited speaker**

Title presentation: Neuronal cholinergic toxins as possible drugs for lung cancer treatment

Author: Patrizia Russo (National Institute for Research on Cancer, Genova, Italy)

Published on: Goudey-Perriere, Ed. Toxines et fonctions cholinergiques neuronales et non neuronales. Lavoisier 2008, pp63-67

### **6. MULTIDISCIPLINARY WORKSHOP IN THORACIC MEDICINE December 16-17,2011 Centro Oncologico Fiorentino – Sesto Fiorentino (FI)**

#### **Invited Speaker**

Title presentation: Nuove conoscenze: nel mondo della biologia molecolare

Author: P. Russo

### **7. 3rd International Symposium on Non-Neuronal Acetylcholine, August 24-26, 2011, Groningen, the Netherlands.**

#### **Invited Speaker**

Title presentation: Nicotinic receptor and tobacco-related cancer

Authors: Patrizia Russo, Alessio Cardinale, Stefano Margaritora, Alfredo Cesario

Published on: Life Sci. 2012 Nov 27;91(21-22):969-1138.

### **8. World Cancer Congress 2012 Beijing, China**

#### **Invited Speaker**

Title presentation: Tobacco and Lung Cancer: specific role of nicotine

Author: P Russo

**9.** The 22th ISFN Annual Meeting Eilat 2013

**Invited Speaker**

Title of presentation: An old factor for a new "era" : alpha7 -nAChR.

Authors: Russo P , Del Bufalo A. Cesario A.

**10.** The 23th ISFN Annual Meeting Eilat 2014

**Invited Speaker**

Title of presentation: Effect of CHRNA7 genotypes on the cognitive response to acetylcholinesterase inhibitor (AChEI) treatment (Donepezil) at Different Stages of Alzheimer's Disease

Authors: Russo P, Marra C.

**11.** The 24th ISFN Annual Meeting Eilat 2015

Title of presentation: Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitor Donepezil in Patients with Alzheimer's Disease

Authors: Russo P , Del Bufalo A.

**12. Invited Speaker** at the CME Course 'Use of Biomarkers in Clinical and Epidemiological Studies, of certain cross-cutting interest in clinical and research activities IRCCS San Raffaele- Roma 16/12/2016

**13.** The 26th ISFN Annual Meeting Eilat 2017

Title of presentation: Effect of FKBP5 Polymorphism on Emotional Response to Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) patients

Author: Russo P., Prinzi. G, Malavolta M.

**14.** Italy-Israel Cooperation Workshop

Advanced Health Care Management and Technological Advances in Tele-Neurorehabilitation.

**Invited Speaker**

Roma, 23/10/2018, Ministero Affari Esteri e Cooperazione Internazionale

**-15** Distance learning event titled 'Legislative Decree of June 8, 2001, No. 231' (Module 1); 'The organizational, management, and control model 231' (Module 2). IRCCS San Raffaele Pisana Roma, Via di Val Cannuta 247, 00166. 10/10/2018

**-16** Training event titled 'The future of ethics committees between rules and technologies. IRCCS San Raffaele Pisana Roma, Via di Val Cannuta 247, 00166.'" 12/03/2019

**-17** "State of the Art" meeting "Tebonim-EGb 761": Potential Clinical Applications. IRCCS San Raffaele Pisana Roma, Via di Val Cannuta 247, 00166.09/05/2019

**-18** VLCKD Endocrinology and Beyond. IRCCS San Raffaele Pisana Roma, Via di Val Cannuta 247, 00166.08/06/2019

**-19** Rehabilitation: A Future Challenge of Robotics IRCCS San Raffaele Pisana Roma, Via di Val Cannuta 247, 00166.09/12/2019

**-20 ERS** (European respiratory Society) Vienna 7-9, 2020

**Invited Speaker.** Expert view on Smoking, nicotine and COVID-19 myths and facts. What is the evidence?  
Title of presentation "COVID-19 and Smoking. Is Nicotine the Hidden Link?"

-21 Information and Training Course 'Covid-19 Risk for Health and Healthcare Operators'. Corso FAD.  
04/01/2021

-22 Streaming Course

**Invited Speaker**

COVID-19: Separating Facts from Myths 11/02/2021

-23 Cardiometabolic & Venous diseases Forum. Moving towards holistic approach to patients with multi-morbidities

**Scientific Advisory Board**

Dubrovnik 3-4/06/2023

-24 XIX CONGRESSO NAZIONALE SITAB Tabagismo: Nuovi Prodotti, nuove sfide Smoking: new products, new challenge. Connected to the ENSP - European Conference on Tobacco Control ( ECTC), 10-12 ottobre 2023

**Invited Speaker**

Impatto del fumo di tabacco su gusto e olfatto

Impact of tobacco smoke on taste and smell

Firenze 12-13/10/2023

-25 How the management of the decompensated patient has changed

**Scientific Advisory Board**

Roma 10-11/11/2023

-26 2nd European Congress on Microbiology Vienna 20-21/11/2023

**Invited Speaker**

Title of presentation: The Severity and Mortality of COPD Remain Unaffected by Infection with JC Polyomavirus (JCPyV), BK Polyomavirus (BKPyV), Influenza Virus (H1N1), or Torquetenovirus (TTV) in COPD Smokers. A Comparison with SARS-CoV-2 and the Specific Role of Nicotine in SARS-CoV-2 Disease.

Russo P, Proietti S, Ilari S, Limongi D, Maggi F, Bonassi S.

-27 2nd European Congress on Microbiology Vienna 20-21/11/2023

**Invited Key Note Speaker**

Title of presentation: TTV-virome prediction of dysregulated immunity and clinical differential diagnosis

-28 -2nd European Congress on Microbiology Vienna 20-21/11/2023

**Chairman Day 2**

## Appendix C: Scientific Publications: today-2009

1. **Russo P**, Milani F, De Iure A, Proietti S, Limongi D, Prezioso C, Checconi P, Zagà V, Novazzi F, Maggi F, Antonelli G, Bonassi S. Effect of Cigarette Smoking on Clinical and Molecular Endpoints in COPD Patients. *Int J Mol Sci*. 2024, in press
2. Gallus S, Bosetti C, Gorini G, Stivala C, Boffi C, Lugo A, Carrera G, Veronene C, Santucci C, Pacifici C, Tinghino B, Zagà V, **Russo P**, Cattaruzza MS and the COSMO-IT Investigators The association between tobacco smoking, second-hand smoke and novel products, and COVID-19 severity and mortality in Italy. Results from the COSMO-IT study. *Epidemiol*. 2023 Jul 5;33(7):367-371.
3. Sansone L, Milani F, Fabrizi R, Belli M, Cristina M, Zagà V, de Iure A, Cicconi L, Bonassi S, **Russo P**. Nicotine: From Discovery to Biological Effects. *Int J Mol Sci*. 2023 Sep 26;24(19):14570.
4. Ilari S, Proietti S, **Russo P**, Malafoglia V, Gliozzi M, Maiuolo J, Oppedisano F, Palma E, Tomino C, Fini M, Raffaelli W, Mollace V, Bonassi S, Muscoli C. A Systematic Review and Meta-Analysis on the Role of Nutraceuticals in the Management of Neuropathic Pain in *In Vivo* Studies. *Antioxidants (Basel)*. 2022 Nov 28;11(12):2361.
5. Sansone L, de Iure A, Cristina M, Belli M, Vitiello L, Marcolongo F, Rosellini A, Macera L, Spezia PG, Tomino C, Bonassi S, Russo MA, Maggi F, **Russo P**. Nicotine in Combination with SARS-CoV-2 Affects Cells Viability, Inflammatory Response and Ultrastructural Integrity. *Int J Mol Sci*. 2022 Aug 22;23(16):9488.
6. Vitiello L, Ilari S, Sansone L, Belli M, Cristina M, Marcolongo F, Tomino C, Gatta L, Mollace V, Bonassi S, Muscoli C, **Russo P**. Preventive Measures against Pandemics from the Beginning of Civilization to Nowadays-How Everything Has Remained the Same over the Millennia. *J Clin Med*. 2022 Apr 1;11(7):1960.
7. Vitiello L, Gatta L, Ilari S, Bonassi S, Cristina M, Ciatti F, Fini M, Proietti S, **Russo P**, Tomino C, Limongi D. Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies. *Front Immunol*. 2022 Mar 10;13:836495.
8. Ilari S, **Russo P\***, Proietti S, Vitiello L, Muscoli C, Tomino C, Milic M, Bonassi S. DNA damage in dementia: Evidence from patients affected by severe Chronic Obstructive Pulmonary Disease (COPD) and meta-analysis of most recent literature. *Mutat Res Genet Toxicol Environ Mutagen*. 2022 Jun;878:503499. (\* Corresponding Author)
9. Marcolongo F, Scarlata S, Tomino C, De Dominicis C, Giacconi R, Malavolta M, Bonassi S, **Russo P\***, Prinzi G. Psycho-cognitive assessment and quality of life in older adults with chronic obstructive pulmonary disease-carrying the rs4713916 gene polymorphism (G/A) of gene FKBP5 and response to pulmonary rehabilitation: a proof of concept study. *Psychiatr Genet*. 2022 Jun 1;32(3):116-124. (\* Corresponding Author)
10. Marcolongo F, Ottaviani M, Romano P, Bonassi S, Garramone A, Infarinato F, Patrizia Russo\*, Tamburrano A, Tomino C, Prinzi G. The role of resilience and coping among Italian healthcare workers during the COVID-19 pandemic. *Med Lav*. 2021 Dec 23;112(6):496-505(\* Corresponding Author)
11. Ilari S, Vitiello L, **Russo P\***, Proietti S, Milić M, Muscoli C, Cardaci V, Tomino C, Bonassi G, Bonassi S. Daily Vegetables Intake and Response to COPD Rehabilitation. The Role of Oxidative Stress, Inflammation and DNA Damage. *Nutrients*. 2021 Aug 14;13(8):2787. (\* Corresponding Author)
12. Tomino C, Ilari S, Solfrizzi V, Malafoglia V, Zilio G, **Russo P\***, Proietti S, Marcolongo F, Scapagnini G, Muscoli C, Rossini PM. Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®). *Pharmaceuticals (Basel)*. 2021 Apr 1;14(4):305. (\* Corresponding Author)

13. Bonassi S, Ceppi M, Møller P, Azqueta A, Milić M, Neri M, Brunborg G, Godschalk R, Koppen G, Langie SAS, Teixeira JP, Bruzzone M, Da Silva J, Benedetti D, Cavallo D, Ursini CL, Giovannelli L, Moretti S, Riso P, Del Bo' C, **Russo P**, Dobrzyńska M, Goroshinskaya IA, Surikova EI, Staruchova M, Barančokova M, Volkovova K, Kažimirova A, Smolkova B, Laffon B, Valdiglesias V, Pastor S, Marcos R, Hernández A, Gajski G, Spremo-Potparević B, Živković L, Boutet-Robinet E, Perdry H, Lebailly P, Perez CL, Basaran N, Nemeth Z, Safar A, Dusinska M, Collins A; hCOMET project. DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death *Sci Rep*. 2021 Aug 18;11(1):16793.
14. Maggi F, Rosellini A, Spezia PG, Focosi D, Macera L, Lai M, Pistello M, de Iure A, Tomino C, Bonassi S, **Russo P**. nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. *ERJ Open Res*. 2021 Apr 12;7(2):00713-2020..
15. Lupacchini L, Maggi F, Tomino C, De Dominicis C, Mollinari C, Fini M, Bonassi S, Merlo D, **Russo P**. Nicotine changes airway epithelial phenotype and may increase the SARS-COV-2 infection severity. *Molecules*, 2020 Dec 28;26(1):E101. doi: 10.3390/molecules26010101.
16. Cattaruzza MS, Gorini G, Bosetti C, ...**Russo P**,.....Tascini C, Tinghino B. Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy). *Acta Biomedica*, 2020, 91(3), pp. 1–6, e2020062
17. **Russo P**, Bonassi S, Giacconi R, Malavolta M, Maggi F. COVID-19 and smoking: Is nicotine the hidden link? *European Respiratory Journal*, 2020, 55(6), 2001116.
18. Santoro A, Tomino C, Prinzi G, Cardaci V, Fini M, Macera L, **Russo P**, Maggi F. Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens. *Curr Med Chem*. 2020;27(18):2931-2948
19. **Russo P**, Tomino C, Santoro A, Prinzi G, Proietti S, Kisialiou A, Cardaci V, Fini M, Magnani M, Collacchi F, Provinciali M, Giacconi R, Bonassi S, Malavolta M. FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting. *Int J Mol Sci*. 2019 Apr 24;20(8). pii: E2024.
20. Santoro A, Tomino C, Prinzi G, Lamonaca P, Cardaci V, Fini M, **Russo P**. Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. *Recent Pat Anticancer Drug Discov*. 2019;14(1):39-52.
21. **Russo P**, Lamonaca P, Milic M, Rojas E, Prinzi G, Cardaci V, Vitiello L, Proietti S, Santoro A, Tomino C, Fini M, Bonassi S. Biomarkers of DNA damage in COPD patients undergoing pulmonary rehabilitation: Integrating clinical parameters with genomic profiling. *Mutat Res*. 2019 Jul;843:111-117.
22. **Russo P**, Prinzi G, Lamonaca P, Cardaci V, Fini M. Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD). *Curr Med Chem*. 2018 May 13.
23. **Russo P**, Lococco F, Kisialiou A, Prinzi G, Lamonaca P, Cardaci V, Fini M. Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations. *Curr Med Chem*. 2018 May 31
24. Prinzi G, Santoro A, Lamonaca P, Cardaci V, Fini M, **Russo P**. Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. *Mar Drugs*. 2018 Sep 4;16(9). pii: E313
25. **Russo P**, Prinzi G, Proietti S, Lamonaca P, Frustaci A, Boccia S, Amore R, Lorenzi M, Onder G, Marzetti E, Valdiglesias V, Guadagni F, Valente MG, Cascio GL, Fraietta S, Ducci G, Bonassi S. Shorter telomere length in schizophrenia: Evidence from a real-world population and meta-analysis of most recent literature. *Schizophr Res*. 2018 Jul 9. pii: S0920-9964(18)30430-4.
26. Bonassi S, Prinzi G, Lamonaca P, **Russo P**, Paximadas I, Rasoni G, Rossi R, Ruggi M, Malandrino S, Sánchez-Flores M, Valdiglesias V, Benassi B, Pacchierotti F, Villani P, Panatta M, Cordelli E. Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect®Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx]. *BMC Complement Altern Med*. 2018 Jan 22;18(1):22.
27. **Russo P**, Prinzi G, Kisialiou A, Cardaci V, Stirpe E, Conti V, Fini M, Bonassi S. Action plans and coping strategies in elderly COPD patients influence the result of pulmonary rehabilitation: an observational study. *Eur J Phys Rehabil Med*. 2017 Apr 14.

28. Lamonaca P, Prinzi G, Kisialiou A, Cardaci V, Fini M, **Russo P**. Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. *Mar Drugs*. 2017 Mar 20;15(3).
29. **Russo P**, Kisialiou A, Moroni R, Prinzi G, Fini M. Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease. *Curr Drug Targets*. 2017;18(10):1179-1190.
30. **Russo P**, Del Bufalo A, Fini M. Conopeptides in addiction disorders treatment. *IJARCS* 2:37-42, 2015.
31. **Russo P**, Kisialiou A, Lamonaca P, Moroni R, Prinzi G, Fini M. New Drugs from Marine Organisms in Alzheimer's Disease. *Mar. Drugs* 2015 Dec 25;14(1):5.
32. Lococo F, Cesario A, Del Bufalo A, Ciarrocchi A, Prinzi G, Mina M, Bonassi S, **Russo P**. Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach. *Curr Med Chem*. 2015;22(32):3655-75.
33. **Russo P**, Del Bufalo A, Fini M. Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical-clinical evaluation in a system medicine perspective. *EXCLI Journal* 2015;14:228-36.
34. Milić M, Frustaci A, Del Bufalo A, Sánchez-Alarcón J, Valencia-Quintana RI, **Russo P**, Bonassi S DNA damage in non-communicable diseases: A clinical and epidemiological perspective. *Mut Res*, in press.
35. **Russo P**, Del Bufalo A, Salinaro G, Milic M, Fini M, Cesario A. Cholinergic receptors as target for cancer therapy in a systems medicine perspective. *Curr Mol Med*. 2014;14(9):1126-38
36. Del Bufalo A, **Russo P**, Milic C, Pristipino C, Fini M, Cesario A. Systems biology and Systems medicine: The technological tools of the system approaches to complexity. *Chemistry J*, 2014 in press.
37. Del Bufalo A, Cesario A, Salinaro G, Fini M, **Russo P**. Alpha9 Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain. *Curr Pharm Des*. 2014;20(38):6042-7.
38. **Russo P**, Fini M, Cesario A. Disease control and active and healthy ageing: New paradigms of therapeutic strategy. *Curr Pharm Des*. 2014;20(38):5919-20.
39. Cesario A, Auffray C, **Russo P**, Hood L.P4 Medicine Needs P4 Education. *Curr Pharm Des*. 2014;20(38):6071-2.
40. **Russo P**, Del Bufalo AD, Frustaci A, Fini M, Cesario A. Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease:  $\alpha 7$ -nAChR Agonists in Human Clinical Trials. *Curr Pharm Des*. 2014;20(38):6014-21.
41. Cesario A., et al (48 Authors) (**Russo P** in 37), A Systems Medicine Clinical Platform for Understanding and Managing Non-Communicable Diseases. *Curr Pharm Des*. 2014;20(38):5945-56.
42. Antonicelli A, Cafarotti S, Indini A, Galli A, Russo A, Cesario A, Lococo FM, **Russo P**, Mainini AF, Bonifati LG, Nosotti M, Santambrogio L, Margaritora S, Granone PM, Dutly AE. EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. *Int J Med Sci*. 2013;10(3):320-30.
43. **Russo P**, Cardinale A, Margaritora S, Cesario A. Nicotinic receptor and tobacco-related cancer. *Life Sci*. 2012 Nov 27;91(21-22):1087-92
44. **Russo P**, Frustaci A, Del Bufalo A, Fini M, Cesario A. Multitarget drugs of plants origin acting on Alzheimer's disease. *Curr Med Chem*. 2013;20(13):1686-93.
45. **Russo P**, Frustaci A, Del Bufalo A, Fini M, Cesario A. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors. *Curr Med Chem*. 2013;20(8):976-83.
46. Lococo F, Cesario A, Petracca-Ciavarella L, Granone P, **Russo P**. Role of CHRNA5-A3 genetic Locus variants and developing drug for chronic obstructive pulmonary disease. *Curr Med Chem*. 2012;19(34):5863-70.
47. **Russo P**, Del Bufalo A, Cesario A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. *Curr Med Chem*. 2012;19(31):5287-93.
48. **Russo P**, Cesario A. New anticancer drugs from marine cyanobacteria. *Curr Drug Targets*. 2012 Jul;13(8):1048-53.
49. **Russo P**, Cesario A, Cardinale A. Presentation to the special issue: " $\alpha 7$ -nicotinic receptor ( $\alpha 7$ -nAChR): one target different diseases". *Curr Drug Targets*. 2012 May;13(5):573.



50. **Russo P**, Cesario A, Fini M. Concluding notes of special issue " $\alpha$ -7 nicotinic receptor ( $\alpha$ 7-nAChR): one target different diseases". *Curr Drug Targets*. 2012 May;13(5):726-7.
51. **Russo P**, Nastrucci C, Alzetta G, Szalai C. Tobacco habit: Historical, cultural, neurobiological and genetical features of people's relationship with an addictive drug. *Persp. Biol Med.*, November 2011, in press.
52. **Russo P.**, Cardinale A, Schuller H. A new "era" for  $\alpha$ 7- nAChR. *Curr Drug Target* 2012, in press.
53. **Nastrucci C, Russo P.**  $\alpha$ 7- nAChR in airway respiratory epithelial cells. *Curr Drug Target* 2012, in press.
54. Cesario A, **Russo P**, Nastrucci C, Granone P. Is  $\alpha$ 7- nAChR: possible target for lung cancer and malignant pleural mesothelioma treatment? *Curr. Drug Target*. 2012; in press.
55. **Russo P**, Taly A.  $\alpha$ 7-Nicotinic Acetylcholine Receptors: an old actor for new different roles. *Curr Drug Target* 2012, in press.
56. Cardinale A, Cesario A, Nastrucci C, **Russo P.** Nicotine: specific role in cell angiogenesis, proliferation and apoptosis. *Crit Rev Toxicol.* 2012; 42 : 68-89
57. Nastrucci C, **Russo P.** .New anticancer agents derived from marine organisms. *Recent Patents on Anti-Cancer Drug Discovery* May 2012, in press.
58. Russo P, Cardinale A, Margaritora S, Cesario A. Nicotinic receptor and tobacco related cancer. *Life Sciences*, 2012 in press.
59. **Russo P**, Nastrucci, Cesario A. From the sea to antineoplastic therapy. *Curr Med Chem*. 2011, ahead in publication.
60. **Russo P**, Cesario A, Rutella S, Veronesi G, Spaggiari L, Galetta D, Margaritora S, Granone P, Greenberg DS. Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. *Curr Med Chem*. 18(1):91-112, .2011.
61. Viale M, Cordazzo C, de Toter D, Budriesi R, Rosano C, Leoni A, Ioan P, Aiello C, Croce M, Andreani A, Rambaldi M, **Russo P**, Chiarini A, Spinelli. D. Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. *Invest New Drugs*. 29(1):98-109, 2011.
62. Margaritora S, Cesario A, Cusumano G, Cafarotti S, Corbo GM, Ferri L, Ceppi M, Meacci E, Valente S, D'Angelillo RM, **Russo P**, Porziella V, Bonassi S, Pasqua F, Sterzi S, Granone P. Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery. *J Thorac Cardiovasc Surg*. 139:1457-63, 2010.
63. Di Vinci A, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C, Allemanni G, **Russo P**, Dominioni L, Romani M. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. *Int J Oncol*. 2009 Feb;34(2):449-56.
64. Gallus S, Tramacere I, La Vecchia C, Colombo P, Zuccaro P, Paleari L, Cesario A, **Russo P**, Apolone G. Use of pharmacotherapy for smoking cessation in Italy. *Arch Intern Med*. 2009 Nov 9;169(20):1927-8.
65. Cesario A, Dall'Armi V, Cusumano G, Ferri L, Margaritora S, Cardaci V, Cafarotti S, **Russo P**, Paleari L, Sterzi S, Pasqua F, Bonassi S, Granone P. Post-operative pulmonary rehabilitation after lung resection for NSCLC: a follow up study. *Lung Cancer*. 2009 Nov;66(2):268-9.
66. Ciarlo M, **Russo P**, Cesario A, Ramella S, Baio G, Neumaier CE, Paleari L. Use of the semiconductor nanotechnologies "quantum dots" for in vivo cancer imaging. *Recent Pat Anticancer Drug Discov*. 2009 Nov;4(3):207-15.
67. Ramella S, Trodella L, Mineo TC, Pompeo E, Stimato G, Gaudino D, Valentini V, Cellini F, Ciresa M, Fiore M, Piermattei A, **Russo P**, Cesario A, D'Angelillo RM. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. *Int J Radiat Oncol Biol Phys*. 2010 Jan 1;76(1):110-5.
68. Paleari L, Cesario A, Fini M, **Russo P.**  $\alpha$ 7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? *Drug Discov Today*. 2009 Sep;14(17-18):822-36.
69. Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, **Russo P.** Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. *Curr Med Chem*. 2009;16(14):1688-703.

## Scientific Publications 1981-2008

70. Parodi S., Taningher M., **Russo P.**, Pala M., Tamaro M. and Monti-Bragadin C.: DNA-damaging activity "in vivo" and bacterial mutagenicity of sixteen aromatic amines and azo-derivatives, as related quantitatively to their carcinogenicity. *Carcinogenesis* 2: 1317-1326, 1981 (I. F. = 4.118).
71. Pala M., **Russo P.**, Nicolò G., Santi L. and Parodi S.: DNA damage in liver of mice treated with N-nitrodimethylamine. *Mutat. Res.* 103: 207-211, 1982 (I.F. = 2.107).
72. Parodi S., Pala M., **Russo P.**, Zunino A., Balbi C., Albini A., Valerio F., Cimberle MR and Santi L.: DNA damage in liver, kidney, bone marrow and spleen of rats and mice treated with commercial and purified aniline as determined by alkaline elution assay and sister chromatid exchange induction. *Cancer Res.* 42: :2277-2283, 1982 (I. F. = 8.614).
73. Parodi S., Santi L., **Russo P.**, Albini A., Vecchio D., Pala M., Ottaggio L. and Carbone A.: DNA damage induced by Auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (Alkaline elution and SCE induction). *J. Tox. and Env. Health* 9:941-952, 1982 (I.F. = 2.349).
74. **Russo P.**, Pala M., Nicolò G., Santi L. and Parodi S.: DNA damage in liver of rats treated with Nitrofurantoin. *Mutat. Res.* 105:377- 382, 1982 (I.F. = 2.107).
75. Parodi S., Balbi C., Taningher M., Pala M., **Russo P.**, Abemoschi ML and Santi L.: Decreased viscosity of rat-liver DNA treated by 3`-methyl-4-dimethylaminoazobenzene, detected with a new viscometric approach. *Mutat. Res.* 106:91-99, 1982 (I.F. = 2.107).
76. **Russo P.**, Pala M., Ottaggio L., Vecchio D., Santi L. and Parodi S.: Detectability "in vivo" of stabilized intercalating agents with the alkaline elution technique. Comparison with "in vivo" sister chromatid exchange induction. *J. Appl. Tox.* 3:58-62, 1983 (I.F. = 1.064).
77. Parodi S., Pala M., **Russo P.**, Balbi C., Abemoschi ML, Taningher M., Zunino A., Ottaggio L., De Ferrari M., Carbone A. and Santi L.: Alkaline DNA fragmentation, DNA disentanglement evaluated viscosimetrically and sister chromatid exchanges, after treatment in vivo with Nitrofurantoin. *Chem. Biol. Inter.* 45:77-94, 1983 (I.F. = 1.887).
78. Parodi S., Taningher M., **Russo P.**, Pala M., Vecchio D., Fassina GF and Santi L.: Quantitative predictivity of the transformation "in vitro" assay compared with Ames test. *J. of Tox. and Env. Health* 12: 483-510, 1983. (I. F. = 2.349)
79. **Russo P.**, Pala M., Parodi S., Ghiara C., Ferrari N. and Vidali G.: Effects of Vitamine E on liver DNA. *Cancer Letters* 25:163-170, 1984 (I.F. = 1.518).
80. De Flora S., **Russo P.**, Pala M., Fassina GF, Zunino A., Bennicelli C., Zancacchi P., Camoirano A. and Parodi S.: Assay of Phenacetin genotoxicity using "in vitro" and "in vivo" test systems. *J. Tox. and Env. Health* 16:355-377, 1985 (I.F. = 2.349).
81. **Russo P.**, Favoni RE, Zarcone D., Miglietta L., Peluso M., Nicolin A., Bignone F. and Parodi S.: Doxorubicin cytotoxicity to P388 lymphocytic leukemia as determined by alkaline elution and established assays. *Anticancer Res.* 6:1297-1304, 1986 (I. F. = 1.375).
82. Taningher M., Bordone R., **Russo P.**, Grilli S., Santi L. and Parodi S.: Major discrepancies between results obtained with two different methods for evaluating DNA damage: alkaline elution and alkaline unwinding. Possible explanations. *Anticancer Res.* 7:669-680,1987 (I.F. = 1.375).
83. **Russo P.**, Taningher M., Pala M., Pisano V., Pedemonte P., DeAngeli M.T., Carlone S., Santi L., and Parodi S.: Characterization of the effects induced on DNA in mouse and hamster cells by Lithocolic acid. *Cancer Res.* 47:2866-2874, 1987 (I.F. = 8.614).
84. Parodi S., Abemoschi ML, Balbi C., De Angeli MT, Pala M., **Russo P.**, Taningher M. and Santi L.: DNA damage in mouse and rat liver by caprolactam and benzoin, evaluated with three different methods. *Mutat. Res.* 224:379-384, 1989 (I.F. = 2.107).

85. Tornaletti S., **Russo P.**, Parodi S. and Pedrini AM: Studies on DNA binding of caffeine and derivatives: evidence of intercalation by DNA-unwinding experiments. *Biochim. Biophys. Acta.* 1007:112-115, 1989 (I.F. = 2.590).
86. Mazzoni A., Trave F., **Russo P.**, Nicolin A. and Rustum YM: Generation and characterization of low-degree drug resistant human tumor cell line. *Oncology* 47: 488-494, 1990 (I.F. = 2.684).
87. Viganì A., Chiara S., Miglietta L., Repetto L., Conte PF, Cimoli G., Morelli L., Billi G., Parodi S. and **Russo P.**: Effect of recombinant human Tumor Necrosis Factor on A2774 human ovarian cancer cell line: potentiation of Mitoxantrone cytotoxicity. *Gynecol. Oncol.* 41: 52-55, 1991 (I.F. = 1.860).
88. **Russo P.**, Poggi L., Parodi S., Pedrini AM, Kohn KW and Pommier Y.: Production of protein-associated DNA breaks by 8- methoxycaffeine, caffeine and 8-chlorocaffeine in isolated nuclei from L1210 cells: comparison with those produced by topoisomerase II inhibitors. *Carcinogenesis* 12: 1781-1790, 1991 (I.F. = 4.118).
89. Cimoli G., **Russo P.**, Billi G., Mariani GL, Rovini E. and Venturini M. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on human ovarian cancer cells. *Jpn. J. Cancer Res.*, 82: 1196-1198, 1991 (I.F. = 2.117).
90. **Russo P.**, Parodi S. ,Billi G., Oliva C., Venturini M., Noviello E. and Conte PF: Potentiation by Tumor Necrosis Factor of Mitoxantrone cytotoxicity to human ovarian cancer cell lines. *Jpn. J. Cancer Res.* 83: 684-687, 1992 (I.F. = 2.117).
91. Billi G., Venturini M., Piccini D., Parodi S., Rosso R., Conte PF and **Russo P.**: Synergistic cytotoxic effects of recombinant human tumor necrosis factor and etoposide (VP16) or doxorubicin on A2774 human epithelial ovarian cancer cell line. *Int. J. Gynecol. Cancer*, 2: 147-151, 1992. (I.F. = 0.396)
92. Cimoli G., Valenti M., Venturini M., Conte PF and **Russo P.**: Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and Mitoxantrone on primary culture of human ovarian cancer cells. *Anticancer Res.* 12: 1411-1414, 1992 (I.F. = 1.375).
93. Oregno G., Noviello E., Cimoli G., Pagnan G., Parodi S., Venturini M., Conte PF, Schenone F., Conzi GF and **Russo P.**: Potentiation of Topoisomerase I and II inhibitors cell killing by Tumor Necrosis Factor: relationship to DNA strand breakage formation. *Jpn. J. Cancer Res.* 83: 1132-1136, 1992 (I.F. =2.117).
94. Valenti M., Cimoli G., Parodi S., Mariani GL, Venturini M., Conte PF, and **Russo P.**: Potentiation of Tumor Necrosis Factor-mediated cell killing by VP16 on human ovarian cancer cell lines. ["in vitro" results and clinical implications]. *Eur. J. Cancer* 29A :1157-1161, 1993 (I. F. = 2.537).
95. Valenti M., Cimoli G., Mariani GL, Conte PF, Parodi S. and **Russo P.**: Potentiation of TNF-mediated cell killing by Mitoxantrone: relationship to DNA single-strand breaks formation. *Biochem Pharmacol.*, 46:1199-1206, 1993 (I.F. = 2.755).
96. Cimoli G., Valenti M., Parodi S., De Sessa F. and **Russo P.**: Circumvention of atypical multidrug resistance with Tumor Necrosis Factor. *Jpn. J. Cancer Res.*, 85: 135-138, 1994 (I.F. = 2.117).
97. Cimoli G., Valenti M., Parodi S., Mazzoni A., De Sessa F, Conte PF and **Russo P.**: Reversal of "atypical"- multidrug resistance by recombinant human Tumor Necrosis Factor in the human ovarian cancer cell line A2780-DX3. *Oncology Res.*: 5: 311-323, 1994 (I.F. = 1.992).
98. Noviello E., Aluigi MG, Cimoli G., Rovini E., Mazzoni A., De Sessa F. and **Russo P.**: Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of double-strand breaks. *Mutat. Res.* 311: 21-29, 1994 (I. F. = 2.107).
99. **Russo P.**, Cimoli G, Valenti M, De Sessa F, Parodi S and Pommier Y. Induction of DNA double-strand breaks by 8-methoxycaffeine: cell cycle dependence and comparison with topoisomerase II inhibitors. *Carcinogenesis* 15: 2491-2496, 1994 (I. F. = 4.118).
100. Cimoli G, Valenti M, Parodi S, Mazzoni A, Rovini E, De Sessa F and **Russo P.** Atypical-multi drug resistance in human ovarian cancer cell line A2780 selected for resistance to Doxorubicin (A2780-DX3). *J. Cancer Res Clin Oncol.* 121: 155-163, 1995 (I. F. = 1.052).


101. Morgavi P., Cimoli G., Ottoboni C., Michelotti A., Conte PF., Parodi S. and **Russo P.** Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human Tumor Necrosis Factor. *Anticancer Res.* 15: 1423-1428, 1995 (I. F. = 1.375).
102. Aluigi MG., Debernardis D., Cimoli G., Ottoboni C., Parodi S. and **Russo P.** Tumor necrosis factor and DNA topoisomerase II inhibitors in human ovarian cancer: Potential Role in chemotherapy. *Int. J. Oncol.* 7: 461-467, 1995 (I. F. = 1.381).
103. Guglielmi A, Aschele C, Mori A, Baldo C, **Russo P**, Debernardis D, Valenti M, Bruno S, Baldo C, Taverna M, Rosso R and Sobrero A. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells. *Clin Cancer Res.* 1: 1337-1344, 1995 (I.F. = 3.442).
104. Stanzione S, Cimoli G, Debernardis D, Michelotti A, Conte PF, Parodi S and **Russo P.** Interferon- $\alpha$  or  $\beta$  potentiate platinum analogous in human glioblastoma cell lines. *Mut. Res.* 348: 131-135, 1995 (I.F. = 2.107).
105. Del Mastro L, Venturini M, Giannessi PG, Vigani A, Garrone O, Carnino F, **Russo P**, Galletti PG, Rosso R and Conte PF. Intraperitoneal infusion of recombinant human Tumor Necrosis Factor and Mitoxantrone in neoplastic ascites: a feasibility study. *Anticancer Res.* 15: 2207-2212, 1995 (I. F. = 1.375).
106. Noviello E, Cimoli G, Cosimi A, Allievi E, Galletti P, Parodi S and **Russo P.** Tumour Necrosis Factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. *Cytokine* 8: 330-333, 1996 (I. F. = 2.291).
107. Debernardis D, Cimoli G, Parodi S and **Russo P.** Interactions between Taxol and Camptothecin. *Anti-cancer Drugs*, 7:531-534, 1996 (I.F. = 1.594).
108. Debernardis D, Stanzione S, C. Ottoboni, Clerico L, Mancuso T, Parodi S and **Russo P.** Endogenous TNF enhances topoisomerase II inhibitors activity in human ovarian cancer cell lines. *J. Pharm. Exp. Ther.* 279:84-90, 1996,. (I.F. = 3.300)
109. Noviello E, Allievi E, **Russo P** and Parodi S. Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells. *Anti-Cancer Drug design*, 12:261-276, 1997 (I.F. = 1.937)
110. Debernardis D, Graniela Sirè E, de Feudis P., Vikhanskaya F, Valenti M, **Russo P**, Parodi S, D'Incalci M and Brogginì M. p53 status does not affect sensitivity of human ovarian cancer cell lines to Paclitaxel. *Cancer Res*, 57:870-874, 1997 (I.F. = 8.460).
111. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sirè E, Arzani D, Stanzione S, Parodi S, D'Incalci M, **Russo P** and Brogginì M. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.. *British J. Cancer*, 76 :474-479, 1997. (I.F. = 3.489).
112. Vikhanskaya F, Clerico L, Valenti M, Stanzione S, Brogginì M, Parodi S and **Russo P.** Mechanism of resistance to cisplatin in a human ovarian carcinoma cell line selected for resistance to Doxorubicin. Possible role of p53. *Int. J. Cancer*, 72:155-159, 1997 (I.F. = 3.918).
113. Mancuso T, Aguillar F, Pescarolo MP, Clerico L, **Russo P** and Parodi S. Mutation frequencies at codon 248 of the p53 tumor suppressor gene are not increased in colon cancer cell lines with the RER+ phenotype. *Nuc. Acid Res.* 25:3643-3648, 1997 (I.F. = 5.396).
114. Mancuso T, Crovella S, Casazza S, Pescarolo MP, Clerico L, **Russo P** and Parodi S. A fast and simple in situ-PCR method to detect human papilloma virus infection in archival paraffin-embedded tissues. *Int J. Oncol.* 11: 527-531, 1997 (IF = 2.142).
115. Giorello L., Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagnasco L, **Russo P.** and Parodi S. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc H1-S6A,F8A-type peptide fused to an Internalization sequence. *Cancer Res.* 58 :3654-3659, 1998 (IF = 8.460).
116. Vikhanskaya F, Vignati S, Beccaglia P, Ottoboni C, **Russo P**, D'Incalci M, and Brogginì M. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to taxol by inducing G2 arrest and apoptosis. *Exp. Cell Res.* 241 :96-101, 1998 (I.F. = 3.860).

117. **Russo P**, Ottoboni C, Falugi C, Reinhold W, Riou JF, Parodi S and O'Connor PM. Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116. *Ann. N.Y. Acad. Sciences* 252-256, 1999 (I.F. = 1.381).
118. Paleari L, **Russo P**, Roz L, Cesario A, Pastorino U. Smoking out the cholinergic component in lung cancer *Clin Cancer Res.* 2008 Nov 1;14(21):6742-3.
119. Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M, Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, **Russo P**. Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. *Eur J Cancer.* 2008 Oct;44(15):2296-311.
120. **Russo P**, Paleari L, Granone P, Cesario A, Pastorino U. Computed tomography screening for lung cancer in a high-risk population: update on current status. *J Natl Cancer Inst.* 2008 Jul 16;100(14):1043-4.
121. Paleari L, **Russo P**, Cesario A, Granone P. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2008 Jul;136(1):241-2.
122. Bertolini G, Paleari L, Catassi A, Roz L, Cesario A, Sozzi G, **Russo P**. In vivo Cancer Imaging with Semiconductor Quantum Dots *Current Pharm. Analysis,* 2008 Nov; 4(4): 197-205.
123. Magistrelli P, Neri M, Granone P, Cesario A, Paleari L, **Russo P**. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. *Pancreas.* 2008 Jul;37(1):101-2.
124. Paleari L, Cesario A, Granone P, D'Angelillo RM, **Russo P**. Early detection of cancer: lessons from lung cancer CT screening. *Thorax.* 2008 Jun;63(6):566. Erratum in: *Thorax.* 2008 Sep;63(9):844.
125. Catassi A, Servent D, Paleari L, Cesario A, **Russo P**. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis.. *Mutat Res. Rev.* 2008 Sep-Oct;659(3):221-31.
126. Paleari L, Granone P, Cesario A, **Russo P**. Computed tomography screening for lung cancer: review of screening principles and update on current status *Cancer.* 2008 Jun;112(11):2520-1.
127. Paleari L, Grozio A, Cesario A, **Russo P**.The cholinergic system and cancer *Semin Cancer Biol.* 2008 Jun;18(3):211-7.
128. Paleari L, Granone P, Grozio A, Cesario A, **Russo P**. Commentary: early diagnosis of lung cancer: where do we stand? *Oncologist.* 2007 Dec;12(12):1433-6.
129. D'Angelillo RM, Trodella L, Ramella S, Cellini N, Balducci M, Mantini G, Cellini F, Ciresa M, Fiore M, Evoli A, Sterzi S, **Russo P**, Grozio A, Cesario A, Granone P. Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. *Int J Radiat Oncol Biol Phys.* 2008 Jun 1;71(2):420-7.
130. Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, Paganuzzi M, Cesario A, Granone P, Mourier G, **Russo P**. Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. *Int J Cancer.* 2008 Apr 15;122(8):1911-5.
131. Paleari L, **Russo P**, Cesario A, Granone P. Inflammation and thoracic surgery: a complex interaction *Eur J Cardiothorac Surg.* 2007 Dec;32(6): 950-1.
132. Grozio A, Catassi A, Cavalieri Z, Paleari L, Cesario A, **Russo P**.Nicotine, lung and cancer. *Anticancer Agents Med Chem.* 2007 Jul;7(4):461-6.
133. Cesario A, Ferri L, Galetta D, Cardaci V, Biscione G, Pasqua F, Piraino A, Bonassi S, **Russo P**, Sterzi S, Margaritora S, Granone P Pre-operative pulmonary rehabilitation and surgery for lung cancer..*Lung Cancer.* 2007 Jul;57(1):118-9.
134. Cesario A, Ferri L, Galetta D, Pasqua F, Bonassi S, Cline E, Biscione G, Cardaci V, di Toro S, Zarzana A, Margaritora S, Piraino A, **Russo P**, Sterzi S, Granone P Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer.. *Lung Cancer.* 2007 Aug;57(2):175-80.
135. **Russo P**, Catassi A, Cesario A, Servent D. Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system. *Curr Med Chem.* 2006;13(29):3493-512.

136. Trodella L, De Marinis F, D'Angelillo RM, Ramella S, Cesario A, Valente S, Nelli F, Migliorino MR, Margaritora S, Corbo GM, Porziella V, Ciresa M, Cellini F, Bonassi S, **Russo P**, Cortesi E, Granone P. Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. *Lung Cancer*. 2006 Dec;54(3):331-8.
137. Catassi A, Cesario A, Arzani D, Menichini P, Alama A, Bruzzo C, Imperatori A, Rotolo N, Granone P, **Russo P**. Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. *Cell Mol Life Sci*. 2006 Oct;63(19-20):2377-86.
138. Neri M, Cesario A, Granone P, Dominioni L, Puntoni R, D'Angelillo RM, **Russo P**. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate. *Lung Cancer*. 2006 Sep;53(3):393-5; author reply 397-8.
139. Galetta D, Cesario A, Margaritora S, Porziella V, Piraino A, D'Angelillo RM, Gambacorta MA, Ramella S, Trodella L, Valente S, Corbo GM, Macis G, Mulè A, Cardaci V, Sterzi S, Granone P, **Russo P**. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. *J Thorac Cardiovasc Surg*. 2006 Feb;131(2):314-21. Epub 2006 Jan 18. Erratum in: *J Thorac Cardiovasc Surg*. 2006 Jul;132(1):11.
140. **Russo P**, Catassi A, Cesario A, Imperatori A, Rotolo N, Fini M, Granone P, Dominioni L. Molecular mechanisms of hexavalent chromium-induced apoptosis in human bronchoalveolar cells. *Am J Respir Cell Mol Biol*. 2005 Dec;33(6):589-600.
141. Granone P, Trodella L, D'Angelillo RM, Ramella S, Margaritora S, Porziella V, **Russo P**, Cesario A. Comment on "Post-operative radiotherapy in non small cell lung cancer: update of individual patient data" [*Lung Cancer* 2005;47(1):81-83]. *Lung Cancer*. 2005 Nov;50(2):277-8;
142. Trombino S, Neri M, Puntoni R, Angelini C, Loprevite M, Cesario A, Granone P, Imperatori A, Dominioni L, Ardizzoni A, Filiberti R, **Russo P**. Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. *Clin Chem*. 2005 Jul;51(7):1313-4.
143. Cesario A, Catassi A, Festi L, Imperatori A, Pericelli A, Galetta D, Margaritora S, Porziella V, Cardaci V, Granone P, Dominioni L, **Russo P**. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. *Clin Cancer Res*. 2005 Mar 1;11(5):2026-37.
144. Trombino S, Bisio A, Catassi A, Cesario A, Falugi C, **Russo P**. Role of the non-neuronal human cholinergic system in lung cancer and mesothelioma: possibility of new therapeutic strategies. *Curr Med Chem Anticancer Agents*. 2004 Nov;4(6):535-42.
145. Cesario A, **Russo P**, Viaggi S, Trombino S, Imperatori A, Margaritora S, Dominioni L, Festi L, Porziella V, Granone P. Malignant pleural mesothelioma: time for translational research *Lancet Oncol*. 2004 Oct;5(10): 591-2.
146. Cesario A, Margaritora S, Parodi S, **Russo P**, La Vecchia C, Apolone G, Galetta D, Pezzella F, Granone P. Networking for excellence in lung cancer: paper vs research work. *Lung Cancer*. 2004 Mar;43(3):363-5.
147. Cesario A, Trombino S, Galetta D, Margaritora S, Murolo C, Dominioni L, Imperatori A, Festi L, Granone P, **Russo P**. Non-small cell lung cancer: from cytotoxic systemic chemotherapy to molecularly targeted therapy. *Curr Med Chem Anticancer Agents*. 2004 May;4(3):231-45.
148. Cesario A, Margaritora S, Galetta D, Porziella V, Granone P, D'Angelillo RM, Trodella L, Cardaci V, Sterzi S, **Russo P**. Correspondence re L. J. Wirth et al., Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. *Clin Cancer Res* 2003;9:1698-704. *Clin Cancer Res*. 2004 Apr 15;10(8):2902-3.
149. **Russo P**, Loprevite M, Cesario A, Ardizzoni A. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. *Curr Med Chem Anticancer Agents*. 2004 Mar;4(2):123-38.
150. Tanara G, Falugi C, Cesario A, Margaritora S, **Russo P**, Cosimi A. TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. *Int J Biol Markers*. 2003 Oct-Dec;18(4):280-3.
151. Trombino S, Cesario A, Margaritora S, Granone P, Motta G, Falugi C, **Russo P**. Alpha7-nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-

- activated protein kinase pathway. *Cancer Res.* 2004 Jan 1;64(1):135-45. Erratum in: *Cancer Res.* 2004 Feb 15;64(4):1559.
152. Cesario A, Galetta D, **Russo P**, Margaritora S, Granone P. The role of the surgeon in translational research. *Lancet.* 2003 Sep 27;362(9389):1082.
153. Valente P, Arzani D, Cesario A, Margaritora S, Carbone E, **Russo P**. TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB. *Eur J Cancer.* 2003 Jul;39(10):1468-77.
154. Falugi C, Trombino S, Granone P, Margaritora S, **Russo P**. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability. *Curr Cancer Drug Targets.* 2003 Apr;3(2):109-18.
155. **Russo P**, Arzani D, Trombino S, Falugi C. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor. *Pharmacol Exp Ther.* 2003 Jan;304(1):37-47.
156. **Russo P**, Malacarne D, Falugi C, Trombino S, O'Connor PM. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. *Int J Cancer.* 2002 Jul 20;100(3):266-75.
157. Vikhanskaya F, Falugi C, Valente P, **Russo P**. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. *Int J Cancer.* 2002 Feb 20;97(6):732-9.
158. **Russo P**, Ottoboni C, Malacarne D, Crippa A, Riou JF, O'Connor PM. Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: role of p53. *J Pharmacol Exp Ther.* 2002 Jan;300(1):220-6.
159. **Russo P**, Ottoboni C, Crippa A, Riou JF, O'Connor PM. RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells.. *Int J Oncol.* 2001 Apr;18(4):855-62.
160. Ottoboni C, Crippa A, Falugi C, **Russo P**. Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. *Mutagenesis.* 2001 Sep;16(5):423-30.

Roma, June, 2024

A handwritten signature in black ink that reads "Potirio Russo". The signature is written in a cursive, flowing style.